NewAmsterdam Pharma (NAMS) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.15
- EPS estimate
- −$0.46
- EPS surprise
- +67.62%
- Revenue surprise
- +447.99%
- Revenue
- $19.1M
- Revenue estimate
- $3.5M
- Reported
- Aug 6, 2025
NewAmsterdam Pharma reported Q2 2025 results on August 6, 2025. The company posted a loss of $0.15 per share, narrower than the expected $0.46 loss, a beat of 67.62%. Revenue was $19.1 million, well above the $3.5 million estimate. Compared with Q2 2024, the loss per share narrowed from $0.41, and revenue rose from $2.3 million.
The record here is short. The table holds only four quarters: Q2 2024, Q4 2024, Q1 2025 and Q2 2025, so it shows no complete fiscal year. Every one of them was a loss. The widest was Q4 2024, at $0.93 per share, which missed the $0.49 loss estimate by 91.28%. The other three quarters came in better than forecast. Revenue has been small and uneven, ranging from $2.3 million to $19.1 million, and it topped the estimate in all four quarters.
The table contains no report after August 2025, and with so few rows there is no settled pattern of report dates to project from. The next update to this page will show whether later quarters are added to the record and whether the losses per share keep narrowing.
Earnings history
Quarterly revenue
Frequently asked questions
When did NewAmsterdam Pharma (NAMS) last report earnings?
NewAmsterdam Pharma last reported on Aug 6, 2025, covering fiscal Q2 2025.
Did NAMS beat earnings estimates?
Yes. NewAmsterdam Pharma reported EPS of −$0.15 for Q2 2025 against a −$0.46 estimate — a 67.62% beat.
How much revenue did NAMS report last quarter?
NewAmsterdam Pharma reported $19.1M in revenue for Q2 2025, against a consensus estimate of $3.5M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.